Among the countless members of the immune system, natural killer T cells (NKT cells) are undoubtedly a unique and mysterious group. These cells not only have the properties of T cells, but also have the characteristics of natural killer cells. Although NKT cells account for only about 1% of peripheral blood T cells, they play an indispensable role in fighting infection and regulating immune responses.
NKT cells can be considered a hybrid T cell type that can recognize the CD1d molecule. This antigen-presenting molecule can not only bind to self- and exogenous lipids and glycolipids, but also activate the function of NKT cells. Based on the properties of their T cell receptors, NKT cells can be divided into three main categories, including invariant NKT (iNKT) cells.
Invariant NKT cells are known for their rapid responses to danger signals and pro-inflammatory cytokines and play a key role in modifying immune responses.
The T cell receptors of NKT cells are usually of the αβ type and express a variety of natural killer cell-related molecular markers, such as NK1.1. Within the specific NKT class, invariant NKT cells are highly conserved in mice and humans with their invariant T cell receptor chains. This enables them to rapidly recognize specific lipid antigens during an immune response.
Once activated, NKT cells are able to produce large amounts of interferon gamma, IL-4, and a variety of other cytokines. These cells are not only involved in fighting infection, but also strengthen humoral immunity. NKT cells provide support to B cells, further helping them to respond to microorganisms and vaccines.
The loss of NKT cell function may lead to the development of autoimmune diseases such as diabetes and atherosclerosis.
Abnormalities or limitations of NKT cells may affect the development of a variety of chronic diseases, including autoimmune diseases and cancer. For example, NKT cells play an important role in the development of asthma in humans. They play a key role in maintaining the balance and diversity of the immune system.
Studies on human autoimmune diseases have found that the number of NKT cells in peripheral blood tends to decrease.
As an emerging research topic, the clinical potential of NKT cells is receiving more and more attention. As our understanding of NKT cells improves, future therapies targeting these cells may emerge, particularly in cancer immunotherapy and the management of chronic inflammation. Clinical trials are already underway to explore ways to harness the power of NKT cells to alter immune responses, which could provide us with better treatment options.
Looking to the future, we can't help but wonder, can the study of NKT cells reveal more mysteries about immune system regulation and provide new perspectives for the treatment of diseases?